Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer.
The outcomes for treatment of pancreatic cancer have not improved dramatically in many decades. However, the recent promising results with combination chemotherapy regimens for metastatic disease increase optimism for future treatments. With greater control of overt or occult metastatic disease, there will likely be an expanding role for local treatment modalities, especially given that nearly a third of pancreatic cancer patients have locally destructive disease without distant metastatic disease at the time of death. Technical advances have allowed for the safe delivery of dose-escalated radiation therapy, which can then be combined with chemotherapy, targeted agents, immunotherapy, and nanoparticulate drug delivery techniques to produce novel and improved synergistic effects. Here we discuss recent advances and future directions for multimodality therapy in pancreatic cancer.
Department of Radiation Oncology, The University of Texas MD Anderson Cancer, Houston, TX.
Awalpreet S
AS
Chadha
Department of Radiation Oncology, The University of Texas MD Anderson Cancer, Houston, TX.
Allison
A
Khoo
Department of Radiation Oncology, The University of Texas MD Anderson Cancer, Houston, TX.
Maureen L
ML
Aliru
Department of Internal Medicine, Christian Medical College, Vellore, India.
Harpreet K
HK
Arora
Department of Radiation Oncology, The University of Texas MD Anderson Cancer, Houston, TX.
Jillian R
JR
Gunther
Department of Radiation Oncology, The University of Texas MD Anderson Cancer, Houston, TX. Electronic address: skrishnan@mdanderson.org.
Sunil
S
Krishnan
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods / Q000639:trends; D006801:Humans; D007167:Immunotherapy; D036103:Nanotechnology; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000628:therapy*; D011878:Radiotherapy
D000970:Antineoplastic Agents